Simon Cooper
Chief Tech/Sci/R&D Officer chez MORPHIC HOLDING, INC.
Fortune : - $ au 31/03/2024
Profil
Simon Cooper is currently the Chief Medical Officer at Morphic Therapeutic, Inc. and Morphic Holding, Inc. He previously worked as the Global Program Medical Director at Novartis International AG from 2012 to 2014.
In 2021, he served as the Chief Medical Officer & Senior Vice President at Kadmon Holdings, Inc. He also held the position of VP, Global Project Head-Immunology & Inflammation at Sanofi SA. From 2021 to 2024, he was the Chief Medical Officer at Keros Therapeutics, Inc. Prior to that, he worked as the Chief Medical Officer at Anokion US, Inc. from 2019 to 2021.
Dr. Cooper completed his undergraduate degree at Newcastle University Medical School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
KEROS THERAPEUTICS, INC.
-.--% | 13/02/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Simon Cooper
| Sociétés | Poste | Début |
|---|---|---|
| MORPHIC HOLDING, INC. | Chief Tech/Sci/R&D Officer | 19/03/2024 |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA. | Chief Tech/Sci/R&D Officer | 01/03/2024 |
Anciens postes connus de Simon Cooper
| Sociétés | Poste | Fin |
|---|---|---|
| KEROS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 12/03/2024 |
| KADMON HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 01/07/2021 |
| Anokion US, Inc. | Chief Tech/Sci/R&D Officer | 01/02/2021 |
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01/07/2014 |
| Sanofi SA | Corporate Officer/Principal | - |
Formation de Simon Cooper
| Newcastle University Medical School | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| KEROS THERAPEUTICS, INC. | Health Technology |
| MORPHIC HOLDING, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Kadmon Holdings, Inc.
 Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
| Sanofi SA | Health Technology |
Morphic Therapeutic, Inc.
Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA. | Health Technology |
| Anokion US, Inc. |
